Advances in chemotherapy against advanced or metastatic colorectal cancer

Digestion

Volumn 77, Issue SUPPL. 1, 2008, Pages 13-22

  Omura, Kenji ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Chemotherapy; Colorectal cancer; Irinotecan; Leucovorin; Molecular targeting; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ALLERGY; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; VOMITING; COLORECTAL TUMOR; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; TREATMENT OUTCOME;

EID: 40949114707     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111483     Document Type: Conference Paper

References (35)

1. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-755.
2. Kubota T, Fujita S, Kodaira S, et al: Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn J Cancer Res 1991;82:476-482.
3. Spears CP, Gustavsson BG, Berne M: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988;48:5894-5900.
4. Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-3775.
5. Madajewicz S, Petrelli N, Rustum YM, et al: Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 1984;44:4667-4669.
6. O'Connell MJ: A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group. Adv Exp Med Biol 1988;244:173-184.
7. De Gramont A, Krulik M, Cady J, et al: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-1503.
8. Weh HJ, Wilke HJ, Dierlamm J, et al: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal cancer: a multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994;5:233-237.
9. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
10. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5927.
11. Wang JC: DNA topoisomerases. Annu Rev Biochem 1985;54:665-697.
12. Saltz LB, Cox JV, Blanke C, et al;Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
13. AndréT, Louvet C, Maindrault-Goebel F, et al;GERCOR: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999;35:1343-1347.
14. Kidani Y, Inagaki K, Iigo M, et al: Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 1978;21:1315-1318.
15. Habala L, Galanski M, Yasemi A, et al: Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives. Eur J Med Chem 2005;40:1149-1155.
16. De Gramont A, Tournigand C, Louvet C, et al; GERCOD: Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. Rev Med Interne 1997;18:769-775.
17. AndréT, Bensmaine MA, Louvet C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.
18. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
19. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
20. Maindrault-Goebel F, Liedo G, Chibaudel B, et al: Final results of OPTIMOX2: a large randomized phase II study of maintenance therapy or chemotherapy-free interval (CFI) after FOLFOX in patients with metastatic colorectal cancer (MCRC) - a GERCOR study. ASCO 2007, abstract 4013.
21. Tournigand C, AndréT, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
22. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-976.
23. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
24. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
25. Kabbinavar FF, Ellis LM: Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens? Clin Colorectal Cancer 2004;4(suppl 2):S69-S73.
26. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
27. Saltz LB, Clarke S, Diaz-Rubio, et al: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: update efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. ASCO 2007, abstract 4028.
28. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
29. Gordon MS, Cunningham D: Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(suppl 3):25-33.
30. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
31. Pfeiffer P, Nielsen D, Yilmaz M, et al: Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007;46:697-701.
32. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO 2007, abstract 4000.
33. Bokemeyer C, Bondarenko I, Makhson A, et al: Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the firstline treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO 2007, abstract 4035.
34. Saltz LB, Lenz HJ, Kindler HL, et al: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-4561.
35. Tappenden P, Jones R, Paisley S, et al: Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1-128, iii-iv.